CLINICAL DATA INTERCHANGE STANDARDS CONSORTIUM INC

Clinical Data Interchange Standards Consortium Inc. specializes in advancing global standards for clinical research data exchange, enabling interoperability across pharmaceutical, regulatory, and academic institutions. Their core capability lies in developing, maintaining, and promoting open data standards such as SDTM, ADaM, and SEND—critical frameworks that ensure consistent, machine-readable formatting of clinical trial data. This work supports regulatory submissions to agencies like the FDA and enhances data quality, reproducibility, and efficiency in drug development pipelines. The organization’s technical expertise centers on metadata modeling, data structure harmonization, and governance of clinical informatics standards, with a strong focus on facilitating collaboration among global stakeholders through consensus-driven processes. Their key differentiator is their role as a neutral, industry-wide consortium that unites regulators, sponsors, and technology providers to drive standardization without commercial bias. The contractor’s primary agency engagement is with the Department of Health and Human Services, where their work supports public health data infrastructure and regulatory science initiatives. Their relationship with HHS is centered on enabling standardized data submission for clinical research, aligning with the agency’s mission to improve public health through evidence-based decision-making. The primary NAICS classification of Periodical Publishers reflects their role in disseminating technical documentation, standards publications, and educational materials that define clinical data formats. This underscores their positioning as a standards-setting body rather than a traditional vendor or service provider. As a non-profit consortium headquartered in Austin, Texas, the organization operates as a membership-driven entity with no government certifications. Its structure enables broad industry participation, and its geographic presence is anchored in the U.S. while serving a global audience of clinical research stakeholders.